In the treatment of atherosclerosis, some researchers have developed collagen type IV-targeted nanoparticles (Col IV NPs) that selectively deliver PAD4 inhibitors to areas of endothelial cell collapse and type IV collagen-rich basement membrane exposure. The gene discussed is PADI4; the disease is atherosclerosis.